KPTIKaryopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Karyopharm (KPTI) Q2 2026 Earnings Call Transcript Biotech pivots to hematology after endometrial cancer setback, faces debt deadline. | ||
 Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call | ||
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program. | ||
 Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint The global, randomised, double-blind, placebo-controlled trial enrolled 257 adults. | ||
 Why Is KPTI Stock Down 69% After-Hours Today? Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. | ||
 Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock? Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | ||